Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Tenaya Therapeutics, Inc. (TNYA) AI Forecast

Our AI detected a significant signal for Tenaya Therapeutics, Inc.. Create a free account to see the exact price target.

✓ Free account • ✓ 30-day free trial

$TNYA Bullish Signal Full forecast available
Sign Up Free

Tenaya Therapeutics, Inc. (TNYA) Stock Forecast 2025

Tenaya Therapeutics, Inc. (TNYA) AI Stock Price Forecast & Investment Analysis

Tenaya Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Tenaya Therapeutics, Inc. (TNYA) - Comprehensive Stock Analysis & Investment Research

Deep dive into Tenaya Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on April 4, 2026, 6:17 a.m. (UTC)

Tenaya Therapeutics, Inc. Investment Summary

When evaluating whether Tenaya Therapeutics, Inc. (TNYA) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Tenaya Therapeutics, Inc. (TNYA) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. The company employs approximately 149 people. With a market capitalization of $151 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Tenaya Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Tenaya Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Tenaya Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Tenaya Therapeutics, Inc.

Sign Up Free
Corporate Identity

Tenaya Therapeutics, Inc. (Stock Symbol: TNYA) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Tenaya Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Tenaya Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Tenaya Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Tenaya Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Tenaya Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Tenaya Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Tenaya Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Tenaya Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Tenaya Therapeutics, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Tenaya Therapeutics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Tenaya Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-103 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 11.20 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Tenaya Therapeutics, Inc. (TNYA) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Tenaya Therapeutics, Inc. stock analysis.

Deep dive into Tenaya Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Tenaya Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Tenaya Therapeutics, Inc.: With a P/E ratio of -2.45, the market sees the stock as potentially undervalued.

P/E Ratio -2.45x
P/B Ratio 1.22x
Market Cap $151M
EPS $-0.94
Book Value/Share $0.57
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Tenaya Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Tenaya Therapeutics, Inc.: An ROE of -116.9% indicates room for improvement in shareholder value creation.

ROE -116.9%
ROA -41.1%
ROIC -101.5%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Tenaya Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Tenaya Therapeutics, Inc.: A current ratio of 11.20 indicates strong liquidity.

Current Ratio 11.20x
Quick Ratio 11.02x
D/E Ratio 0.05x
Financial Leverage 1.13x
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Tenaya Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Tenaya Therapeutics, Inc.: Free cash flow of $-103M indicates cash challenges that need attention.

Operating Cash Flow -$74M
Free Cash Flow -$103M
Capital Spending -$29M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Tenaya Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Tenaya Therapeutics, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Tenaya Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Tenaya Therapeutics, Inc.:

Income Statement
Operating Income -$113M
Net Income -$113M
R&D Expense $82M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 76%
Cash & Short-term Investments 75%
Total Liabilities 12%
Dividend & Shareholder Information
Shares Outstanding 217M
Growth Metrics (YoY)
EPS Growth -120.8%

Latest Tenaya Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Tenaya Therapeutics, Inc. (TNYA) stock price and investment outlook.

More news available

Sign up free to read all 10 news articles and stay updated on market developments.

Sign Up Free to Read More

Tenaya Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Tenaya Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Acumen Pharmaceuticals, Inc. ABOS ██% $188M -1.9x 2.7x
Abpro Holdings, Inc. ABP ██% $310K x 0.0x
Abpro Holdings, Inc. ABPO ██% $460K x x
Arcellx, Inc. ACLX ██% $6.65B -74.1x 16.5x
Alpha Cognition Inc. ACOG ██% $134M x 2.2x
Adaptimmune Therapeutics Plc ADAP ██% $77M -13.2x -11.8x
Adma Biologics, Inc. ADMA ██% $2.17B 14.8x 4.6x
Adaptive Biotechnologies Corp ADPT ██% $2.25B -4.6x 10.3x
Adverum Biotechnologies, Inc. ADVM ██% $95M -1.8x 2.2x
Agenus Inc AGEN ██% $120M 1047.3x 33.5x
Agentix Corp. AGTX ██% $2M x 249.3x
Aim Immunotech Inc. AIM ██% $2M -0.5x 0.9x
Aim Immunotech Inc. AIMI ██% $1M x x
Alector, Inc. ALEC ██% $251M -1.2x 8.2x
Aligos Therapeutics, Inc. ALGS ██% $49M -19.2x 0.9x
Allogene Therapeutics, Inc. ALLO ██% $593M -1.4x 2.0x
Alvotech ALVO ██% $1.13B x x
Amgen Inc AMGN ██% $190.18B 24.7x 22.0x
Apogee Therapeutics, Inc. APGE ██% $5.77B -20.5x 4.3x
Aptose Biosciences Inc. APTOF ██% $4M x x
Argenx Se ARGX ██% $46.03B x x
Armata Pharmaceuticals, Inc. ARMP ██% $378M -1.0x 16.4x
Artiva Biotherapeutics, Inc. ARTV ██% $165M x 1.5x
Leonabio, Inc. ATHA ██% $23M -0.2x 0.9x
Atara Biotherapeutics, Inc. ATRA ██% $42M 1.3x 4.7x
Atyr Pharma Inc ATYR ██% $84M -3.6x 1.2x
Aura Biosciences, Inc. AURA ██% $416M -4.9x 3.0x
Autolus Therapeutics Plc AUTL ██% $374M x 2.1x
Anavex Life Sciences Corp. AVXL ██% $279M -17.3x 2.2x
Bioatla, Inc. BCAB ██% $11M -1.1x 23.3x
Biocardia, Inc. BCDA ██% $12M -0.6x 13.9x
Brainstorm Cell Therapeutics Inc. BCLI ██% $10M -4.9x 6.0x
Biocryst Pharmaceuticals Inc BCRX ██% $2.35B 8.9x 70.5x
Black Diamond Therapeutics, Inc. BDTX ██% $133M 6.0x 1.2x
Beam Therapeutics Inc. BEAM ██% $2.46B -12.6x 2.0x
Biogen Inc. BIIB ██% $26.98B 20.9x 1.5x
Biontech Se BNTX ██% $22.47B x x
Cabaletta Bio, Inc. CABA ██% $269M -1.6x 2.4x
Candel Therapeutics, Inc. CADL ██% $365M -4.6x 7.0x
C4 Therapeutics, Inc. CCCC ██% $262M -2.6x 1.0x
Cidara Therapeutics, Inc. CDTX ██% $6.49B -1.0x 15.4x
Creative Medical Technology Holdings, Inc. CELZ ██% $7M -3.4x 1.0x
Cero Therapeutics Holdings, Inc. CERO ██% $650K x -196.2x
Cullinan Therapeutics, Inc. CGEM ██% $840M -4.1x 2.1x
Compugen Ltd CGEN ██% $211M 3.0x 2.1x
Cg Oncology, Inc. CGON ██% $5.39B x 7.2x
Cognition Therapeutics Inc CGTX ██% $76M -0.5x 2.2x
Coherus Oncology, Inc. CHRS ██% $256M 1.5x 4.2x
Calidi Biotherapeutics, Inc. CLDI ██% $2M -0.9x 0.6x
Cellectis S.A. CLLS ██% $344M x x
Compass Therapeutics, Inc. CMPX ██% $968M -4.8x 4.9x
Mosaic Immunoengineering Inc. CPMV ██% $5M x 20.9x
Caribou Biosciences, Inc. CRBU ██% $142M -1.5x 1.0x
Cardiff Oncology, Inc. CRDF ██% $110M -4.0x 2.4x
Cardiol Therapeutics Inc. CRDL ██% $156M x x
Curis Inc CRIS ██% $22M -0.3x 4.0x
Crispr Therapeutics Ag CRSP ██% $4.70B -12.1x 2.5x
Champions Oncology, Inc. CSBR ██% $82M 32.9x 19.2x
Cel Sci Corp CVM ██% $29M -0.9x 2.6x
Dbv Technologies S.A. DBVT ██% $1.24B -3.3x 7.3x
Dbv Technologies S.A. DBVTF ██% $10K x 0.0x
Ginkgo Bioworks Holdings, Inc. DNA ██% $395M -13.9x 0.8x
Denali Therapeutics Inc. DNLI ██% $3.23B -8.7x 3.2x
Precision Biosciences Inc DTIL ██% $137M -2.2x 1.5x
Dyadic International Inc DYAI ██% $31M -7.3x 25.0x
Editas Medicine, Inc. EDIT ██% $255M -0.8x 9.4x
Eloxx Pharmaceuticals, Inc. ELOX ██% $710K x x
Elutia Inc. ELUT ██% $45M 0.9x 1.6x
Engene Holdings Inc. ENGN ██% $453M 3.7x 1.6x
Entera Bio Ltd. ENTX ██% $53M 8.5x 4.0x
Viskase Holdings, Inc. ENZN ██% $4M x 10.3x
Estrella Immunopharma, Inc. ESLA ██% $45M -3.1x 289.4x
Evaxion A/S EVAX ██% $33M x x
Exelixis, Inc. EXEL ██% $11.56B 14.8x 5.4x
Exozymes Inc. EXOZ ██% $71M x 20.9x
Fate Therapeutics Inc FATE ██% $143M -1.3x 0.7x
4d Molecular Therapeutics, Inc. FDMT ██% $504M -3.0x 1.0x
Fennec Pharmaceuticals Inc. FENC ██% $219M 1758.3x 6.2x
Finch Therapeutics Group, Inc. FNCH ██% $15M 0.5x 1.1x
Futuretech Ii Acquisition Corp. FTII ██% $52M x -0.7x
Futuretech Ii Acquisition Corp. FTIIU ██% $14M x -0.8x
Gilead Sciences, Inc. GILD ██% $174.11B 20.5x 7.7x
Monte Rosa Therapeutics, Inc. GLUE ██% $1.37B 59.5x 5.9x
Genenta Science S.P.A. GNTA ██% $16M x 1.3x
Green Planet Bio Engineering Co. Ltd. GPLB ██% $340K x x
Greenland Mines Ltd GRML ██% $44M x 4.5x
Halozyme Therapeutics, Inc. HALO ██% $7.54B 23.8x 154.4x
Humacyte, Inc. HUMA ██% $131M -3.3x 42.3x
Immunitybio, Inc. IBRX ██% $7.22B -3.6x 57.4x
Inhibikase Therapeutics, Inc. IKT ██% $238M -1.0x 1.4x
Imagenebio, Inc. IMA ██% $56M x 0.4x
Immunocore Holdings Plc IMCR ██% $1.54B x 4.0x
Immatics N.V. IMTX ██% $1.34B x x
Immunovant, Inc. IMVT ██% $5.06B -14.5x 5.1x
In8bio, Inc. INAB ██% $14M x 0.5x
Inhibrx Biosciences, Inc. INBX ██% $873M -6.8x 109.2x
Mink Therapeutics, Inc. INKT ██% $45M -1.5x 6.7x
Inmune Bio, Inc. INMB ██% $33M -2.5x 1.4x
Intensity Therapeutics, Inc. INTS ██% $14M -2.2x 1.2x
Iovance Biotherapeutics, Inc. IOVA ██% $1.41B -4.5x 2.0x
Century Therapeutics, Inc. IPSC ██% $394M -0.7x 2.5x
Invivyd, Inc. IVVD ██% $360M -0.4x 1.5x
Jasper Therapeutics, Inc. JSPR ██% $22M -3.2x 5.4x
Kalaris Therapeutics, Inc. KLRS ██% $136M x 1.7x
Klotho Neurosciences, Inc. KLTO ██% $56M x 5.7x
Kodiak Sciences Inc. KOD ██% $2.64B -2.5x 16.8x
Krystal Biotech, Inc. KRYS ██% $7.56B 36.9x 6.2x
Kymera Therapeutics, Inc. KYMR ██% $6.91B -17.8x 4.4x
Kyverna Therapeutics, Inc. KYTX ██% $530M x 2.3x
Ladrx Corp LADX ██% $20K x 0.1x
Lineage Cell Therapeutics, Inc. LCTX ██% $387M -4.7x 8.7x
Lenz Therapeutics, Inc. LENZ ██% $293M -6.7x 1.0x
Liminatus Pharma, Inc. LIMN ██% $7M x x
Leonabio, Inc. LONA ██% $106M x 3.8x
Lexeo Therapeutics, Inc. LXEO ██% $414M -0.4x 1.7x
Maze Therapeutics, Inc. MAZE ██% $1.43B x 4.0x
Mesoblast Ltd MESO ██% $2.07B x x
Meiragtx Holdings Plc MGTX ██% $737M -3.4x 201.5x
Metagenomi Therapeutics, Inc. MGX ██% $50M x 0.3x
Molecular Partners Ag MOLN ██% $162M x x
Moderna, Inc. MRNA ██% $19.71B -3.2x 2.3x
Neurocrine Biosciences Inc NBIX ██% $13.27B 27.7x 4.1x
Nkgen Biotech, Inc. NKGN ██% $2M -0.1x -0.2x
Neumora Therapeutics, Inc. NMRA ██% $348M -3.9x 3.4x
Novavax Inc NVAX ██% $1.30B 3.0x 40.0x
Ocugen, Inc. OCGN ██% $559M -4.3x 154.7x
Outlook Therapeutics, Inc. OTLK ██% $22M -0.2x 2.1x
Palisade Bio, Inc. PALI ██% $312M -0.2x 2.4x
Passage Bio, Inc. PASG ██% $25M -0.6x 1.3x
Vaxcyte, Inc. PCVX ██% $7.67B -20.4x 2.9x
Biomx Inc. PHGE ██% $22M 1.5x 0.8x
Pluri Inc. PLUR ██% $33M -1.4x 352.9x
Protalix Biotherapeutics, Inc. PLX ██% $176M 41.2x 3.7x
Pharmacyte Biotech, Inc. PMCB ██% $7M 0.3x 0.2x
Prime Medicine, Inc. PRME ██% $599M -1.5x 5.0x
Prokidney Corp. PROK ██% $527M x 0.0x
Pelthos Therapeutics Inc. PTHS ██% $66M x 1.7x
Qiagen N.V. QGEN ██% $8.86B x 2.4x
Quince Therapeutics, Inc. QNCX ██% $5M -1.7x 4.9x
Qrons Inc. QRON ██% $150K x x
Replimune Group, Inc. REPL ██% $606M -3.8x 2.9x
Repligen Corp RGEN ██% $6.66B 136.3x 3.2x
Regenxbio Inc. RGNX ██% $439M -1.8x 4.3x
Relay Therapeutics, Inc. RLAY ██% $1.87B -2.0x 3.3x
Revolution Medicines, Inc. RVMD ██% $19.43B -11.1x 11.9x
Recursion Pharmaceuticals, Inc. RXRX ██% $1.62B -4.7x 1.4x
Sab Biotherapeutics, Inc. SABS ██% $271M 20.4x 1.8x
Sana Biotechnology, Inc. SANA ██% $846M -2.1x 5.3x
Scilex Holding Co SCLX ██% $49M -0.4x 4.5x
Scinai Immunotherapeutics Ltd. SCNI ██% $2M -287.8x 0.3x
Sangamo Therapeutics, Inc SGMO ██% $91M -1.6x 13.1x
Solid Biosciences Inc. SLDB ██% $726M -0.9x 4.0x
Silexion Therapeutics Corp SLXN ██% $4M x 1.6x
Senti Biosciences, Inc. SNTI ██% $26M -1.1x 4.6x
Scholar Rock Holding Corp SRRK ██% $5.35B -18.5x 21.8x
Surrozen, Inc./De SRZN ██% $335M -0.5x 7.3x
Sutro Biopharma, Inc. STRO ██% $392M -1.0x 8.0x
Protara Therapeutics, Inc. TARA ██% $270M -2.1x 1.4x
Tarsus Pharmaceuticals, Inc. TARS ██% $2.99B -12.4x 8.7x
Tc Biopharm (Holdings) Plc TCBPY ██% $10K x 0.0x
Tscan Therapeutics, Inc. TCRX ██% $57M -4.6x 0.5x
Bio-Techne Corp TECH ██% $8.34B 102.8x 4.1x
Tectonic Therapeutic, Inc. TECX ██% $575M -8.9x 2.3x
Instil Bio, Inc. TIL ██% $54M -1.1x 0.5x
Tenaya Therapeutics, Inc. TNYA ██% $151M -2.5x 1.2x
Tourmaline Bio, Inc. TRML ██% $1.23B -3.5x 4.8x
Taysha Gene Therapies, Inc. TSHA ██% $1.25B -3.0x 5.0x
Titan Pharmaceuticals Inc TTNP ██% $6M -0.5x 2.2x
Tevogen Bio Holdings Inc. TVGN ██% $18M x 1274.2x
Twist Bioscience Corp TWST ██% $3.08B -12.6x 6.8x
Voyager Acquisition Corp./Cayman Islands VACH ██% $374M 41.6x 0.0x
Voyager Acquisition Corp./Cayman Islands VACHU ██% $68M 6.7x 0.0x
Valneva Se VALN ██% $530M x x
Vericel Corp VCEL ██% $1.59B 96.5x 4.5x
Vir Biotechnology, Inc. VIR ██% $1.47B -2.0x 1.9x
Vivosim Labs, Inc. VIVS ██% $4M x 0.9x
Vor Biopharma Inc. VOR ██% $882M -0.6x 11.2x
Vaxart, Inc. VXRT ██% $151M 9.3x 1.7x
Voyager Therapeutics, Inc. VYGR ██% $234M 570.6x 1.2x
Windtree Therapeutics Inc /De/ WINT ██% $340K -0.4x 0.1x
X4 Pharmaceuticals, Inc XFOR ██% $402M 6.4x 2.2x
Zeo Scientifix, Inc. ZEOX ██% $17M x 25.0x
Zivo Bioscience, Inc. ZIVO ██% $25M -31.3x 17.0x
Zura Bio Ltd ZURA ██% $559M x 5.5x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Tenaya Therapeutics, Inc. Stock Forecast

How accurate are Tenaya Therapeutics, Inc. stock predictions?

Our AI model shows a 44% Spearman correlation coefficient for TNYA predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Tenaya Therapeutics, Inc. stock price forecasts?

Our analysis considers Tenaya Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Tenaya Therapeutics, Inc. a good investment in 2025?

Based on our AI analysis, Tenaya Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Tenaya Therapeutics, Inc. forecasts updated?

Tenaya Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Tenaya Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...